Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

144.79 +2.06 (+1.44%)
Streaming Delayed Price Updated: 12:11 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
The company is working on a treatment for a disorder than can cause children to begin puberty early. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated  
Via Benzinga
Analyst Ratings for Neurocrine Biosciences
 
Via Benzinga
Analyst Ratings for Neurocrine Biosciences
 
Via Benzinga
Earnings Outlook For Neurocrine Biosciences
 
Via Benzinga
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
 
Via Benzinga
Expert Ratings for Neurocrine Biosciences
 
Via Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
 
Via Benzinga
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
 
Via Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
 
Via Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
 
Via Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
 
Via Benzinga
Neurocrine Biosciences's Earnings: A Preview
 
Via Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
 
Via Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
Expert Ratings for Neurocrine Biosciences
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
Analyst Expectations for Neurocrine Biosciences's Future
 
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
 
Via Benzinga
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
Neurocrine also topped fourth-quarter revenue expectations on Monday. 
Via Investor's Business Daily
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
Neurocrine Biosciences Earnings Preview
 
Via Benzinga
Earnings Scheduled For February 6, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
 
Via Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
 
Via Benzinga
7 A-Rated Stocks to Buy for Less Than $25
These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.